MORELAC OS SOSP 10BUST

OTHER 10.000.000 UFC - 5.000.000 UFC - 4.000.000.000 UFC POLVER FOR ORAL SOSPENSION

active ingredients

Each bag contains: Active ingredient: Lactobacillus acidophilus P-18806 1 x 10⁷ UFC; Lactobacillus delbrueckii P-18805 at least 5 x 10⁶ UFC; Streptococcus thermophilus P-18807 at least 4 x 10⁹ UFC. Excipients with known effects: sucrose, sorbitol, lactose. For the full list of excipients, see paragraph 6.1

Excellent

Silic acid - Sodium saccharin - Aroma banana powder - Aroma apricot powder - Maltodextrin - Crioprotector (Latte scremato - Saccarosio - Sorbitol - Sodium Ascorbato - Tween 80) - Lactose.

Therapeutic indications

Intestinal dysmicrobial syndromes: diarrhoic syndromes and dispeptics from altered bacterial flora (diarrhea, aspecific enteritis, colitis); intestinal dysmicrobism from antibiotics.

Contraindications

Hypersensitivity to active ingredients or any of the excipients listed in paragraph 6.1. Allergy known or suspected of cow milk proteins (see paragraph 4.4).

Population

Population Adults: 1 - 2 bags per day. Pediatric population There are no available data How to administer Dissolving the powder in little water or in a small amount of sugary water or milk.

Conservation

Store the product between + 2 ° C and + 8 °C. The occasional and short stay at room temperature does not significantly compromise product activity.

Warnings

MORELAC contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose mal absorption, should not take this medicine. MORELAC contains milk protein (see paragraph 4.3). MORELAC contains less than 1 mmol (23 mg) of sodium per bag, i.e. essentially ‘without sodium’. MORELAC contains sorbitol. Patients with hereditary fructose intolerance should not be given this medicine. MORELAC contains sucrose. Patients with rare hereditary problems of fructose intolerance, glucose- galactose mal absorption, or sucrasirasis - isomaltasis failure, should not take this medicine. The bacteria contained in MORELAC are sensitive to the main antibiotics. For this reason MORELAC must be taken at least three hours after the administration of antibiotics.

Interactions

Interaction studies have not been carried out.

Effects

Don't notice. Reporting of suspicious adverse reactions The reporting of suspicious adverse reactions occurring after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare workers are required to report any suspected adverse reaction via the national reporting system at the address https://www.aifa.gov.it/content/segnalazioni-reazioni-avverse

Overdosing

No overdosing of the product has been reported.

MORELAC can be used during pregnancy and nursing with breast milk.

Source: Farmadati